StreetInsider.com News Articles

German government to drop variable drug discounting plans - Reuters

Mon, 15 Jun 2026 06:08:37 -0400

German government to drop variable drug discounting plans - Reuters

Mon, 15 Jun 2026 06:08:37 -0400

German government to drop variable drug discounting plans - Reuters

Mon, 15 Jun 2026 06:08:37 -0400

German government to drop variable drug discounting plans - Reuters

Mon, 15 Jun 2026 06:08:37 -0400

German government to drop variable drug discounting plans - Reuters

Mon, 15 Jun 2026 06:08:37 -0400

German government to drop variable drug discounting plans - Reuters

Form 6-K BioNTech SE For: Jun 08

Mon, 08 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260608/26614584.html

Form 6-K BioNTech SE For: Jun 08

Mon, 08 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260608/26614584.html

Form 6-K BioNTech SE For: Jun 08

Mon, 08 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260608/26614584.html

Bernstein SocGen Group Reiterates Market Perform Rating on BioNTech (BNTX)

Fri, 05 Jun 2026 09:00:54 -0400

Bernstein SocGen Group analyst Jeffrey Walch reiterated a Market Perform rating and $96.00 price target on BioNTech (NASDAQ: BNTX).

The analyst commented: "Post-ASCO, pumitamig has the same downside risk as ivonescimab; We sharpen our answer for BNTX post-ASCO. However, we land on the same recommendation: investors should pass on BNTX at this time because of their aggressive pumitamig (PD-L1/VEGF) clinical development plan. We still see a high risk of negative registrational trials for the drug class (along with SMMT’s ivonescimab) due to historical failure to achieve a statistically significant survival benefit. We maintain our perspective that the consensus view of probability

Lilly cuts Germany investment plan in half over healthcare reforms

Wed, 03 Jun 2026 13:17:16 -0400

Investing.com -- Eli Lilly and Company announced Wednesday it will reduce its remaining investment in a German production facility by half, cutting $1.5 billion from its spending plans and eliminating a substantial portion of 1,000 planned jobs.

The Indianapolis-based pharmaceutical company cited proposed healthcare reforms in Germany that aim to lower drug prices as the reason for scaling back the $2.5 billion project in Alzey. Interior work at the site continues and 300 employees have been hired, ensuring the facility will become operational.

Lilly said the decision to expand remaining capacity has been suspended and will depend on whether stable and predictable

Lilly cuts Germany investment plan in half over healthcare reforms

Wed, 03 Jun 2026 13:17:16 -0400

Lilly said the decision to expand remaining capacity has been suspended and will depend on whether stable and predictable

The Multi-Billion-Dollar Search for Better Glioblastoma Treatments

Wed, 03 Jun 2026 09:28:24 -0400

Why Investors Continue Watching One of Oncology's Most Difficult Frontiers

DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types.